Inter J Stomatol ›› 2017, Vol. 44 ›› Issue (3): 325-331.doi: 10.7518/gjkq.2017.03.015

• Reviews • Previous Articles     Next Articles

Drug management of oral submucous fibrosis

Liu Jinli, Chen Fangman, Jiang Lu.   

  1. State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2016-07-15 Revised:2017-01-16 Online:2017-05-01 Published:2017-05-01
  • Supported by:
    This study was supported by the National Natural Science Foundation of China(81670998).

Abstract: As the pathogenesis of oral submucons fibrosis is obscure, this disease is still lack of unified treatment. Drug management remains the major treatment plan. This paper summarizes a wide range of drug management which have been attempted till date, and claims to use different drug depending on the stage of the disease.

Key words: oral submucous fibrosis, drug, treatment progress

CLC Number: 

  • R781.5+9

[1] Singh M, Niranjan HS, Mehrotra R, et al. Efficacy of hydrocortisone acetate/hyaluronidase vs triamcino-lone acetonide/hyaluronidase in the treatment of oral submucous fibrosis[J]. Indian J Med Res, 2010, 131(5):665-669.
[2] Kiran Kumar K, Saraswathi TR, Ranganathan K, et al. Oral submucous fibrosis: a clinico-histopathological study in Chennai[J]. Indian J Dent Res, 2007, 18(3): 106-111.
[3] Haque MF, Meghji S, Nazir R, et al. Interferon gamma(IFN-γ) may reverse oral submucous fibrosis [J]. J Oral Pathol Med, 2001, 30(1):12-21.
[4] Golay A, Ferrara JM, Felber JP, et al. Cholesterol-lowering effect of skim milk from immunized cows in hypercholesterolemic patients[J]. Am J Clin Nutr, 1990, 52(6):1014-1019.
[5] Tai YS, Liu BY, Wang JT, et al. Oral administration of milk from cows immunized with human intestinal bacteria leads to significant improvements of symp-toms and signs in patients with oral submucous fib-rosis[J]. J Oral Pathol Med, 2001, 30(10):618-625.
[6] Jirge V, Shashikanth MC, Ali IM, et al. Levamisole and antioxidants in the management of oral submu-cous fibrosis: a comparative study[J]. J Indian Acad Oral Med Radiol, 2008, 20(4):135.
[7] Lin HJ, Lin JC. Treatment of oral submucous fibro-sis by collagenase: effects on oral opening and eating function[J]. Oral Dis, 2007, 13(4):407-413.
[8] Kakar PK, Puri RK, Venkatachalam VP. Oral sub-mucous fibrosis—treatment with hyalase[J]. J Laryn-gol Otol, 1985, 99(1):57-59.
[9] Auluck A, Rosin MP, Zhang L, et al. Oral submucous fibrosis, a clinically benign but potentially malignant disease: report of 3 cases and review of the literature [J]. J Can Dent Assoc, 2008, 74(8):735-740.
[10] Pineda AM, Tianco EA, Tan JB, et al. Oral pentoxi-fylline and topical clobetasol propionate ointment in the treatment of pretibial myxoedema, with concomi-tant improvement of Graves’ ophthalmopathy[J]. J Eur Acad Dermatol Venereol, 2007, 21(10):1441- 1443.
[11] Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral sub-mucous fibrosis[J]. Indian J Dent Res, 2007, 17(4): 190-198.
[12] Patil S, Maheshwari S. Efficacy of pentoxifylline in the management of oral submucous fibrosis[J]. J Orofac Sci, 2014, 6(2):94.
[13] Lai DR, Chen HR, Lin LM, et al. Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases[J]. J Oral Pathol Med, 1995, 24(9):402-406.
[14] Sharma JK, Gupta AK, Mukhija RD, et al. Clinical experience with the use of peripheral vasodilator in oral disorders[J]. Int J Oral Maxillofac Surg, 1987, 16(6):695-699.
[15] Bhadage CJ, Umarji HR, Shah K, et al. Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis[J]. Clin Oral Investig, 2013, 17(5):1375- 1382.
[16] Chole RH, Gondivkar SM, Gadbail AR, et al. Review of drug treatment of oral submucous fibrosis[J]. Oral Oncol, 2012, 48(5):393-398.
[17] Maher R, Aga P, Johnson NW, et al. Evaluation of multiple micronutrient supplementation in the mana-gement of oral submucous fibrosis in Karachi, Pakis-tan[J]. Nutr Cancer, 1997, 27(1):41-47.
[18] Dhariwal R, Mukherjee S, Mohanty SP, et al. Zinc and vitamin A can minimise the severity of oral submucous fibrosis[J]. BMJ Case Rep, 2010, 2010:bcr1020092348.
[19] Kumar A, Bagewadi A, Keluskar V, et al. Efficacy of lycopene in the management of oral submucous fibrosis[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, 103(2):207-213.
[20] Biswas G, Anup N, Kumawat H. Efficacy of lyco-pene in the management of oral submucous fib-rosis—a randomized clinical trial[J]. Indian J Public Health Res Development, 2015, 6(3):33-37.
[21] Mathew B, Sankaranarayanan R, Nair PP, et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis [J]. Nutr Cancer, 1995, 24(2): 197-202.
[22] Shetty P, Shenai P, Chatra L, et al. Efficacy of spiru-lina as an antioxidant adjuvant to corticosteroid injection in management of oral submucous fibrosis [J]. Indian J Dent Res, 2013, 24(3):347-350.
[23] Patil S, Halgatti V, Maheshwari S, et al. Comparative study of the efficacy of herbal antioxdants oxitard and aloe vera in the treatment of oral submucous fibrosis[J]. J Clin Exp Dent, 2014, 6(3):e265-e270.
[24] 李新民, 唐杰清. 茶色素治疗口腔粘膜下纤维性变的临床观察[J]. 华西口腔医学杂志, 1998, 16(1):50- 52.
Li XM, Tang JQ. Clinical treatment observation of tea pigment for oral submucous fibrosis[J]. West Chin J Stomatol, 1998, 16(1):50-52.
[25] Gupta D, Sharma SC. Oral submucous fibrosis—a new treatment regimen[J]. J Oral Maxillofac Surg, 1988, 46(10):830-833.
[26] Jiang XW, Zhang Y, Yang SK, et al. Efficacy of salvianolic acid B combined with triamcinolone ace-tonide in the treatment of oral submucous fibrosis[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(3):339-344.
[27] Alok A, Singh ID, Singh S, et al. Curcumin-pharma-cological actions and its role in oral submucous fib-rosis: a review[J]. J Clin Diagn Res, 2015, 9(10):ZE01-ZE03.
[28] Rai B, Kaur J, Jacobs R, et al. Possible action me-chanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress[J]. J Oral Sci, 2010, 52(2):251-256.
[29] Joshi J, Ghaisas S, Vaidya A, et al. Early human safety study of turmeric oil(Curcuma longa oil) administered orally in healthy volunteers[J]. J Assoc Physicians India, 2003, 51:1055-1060.
[30] Ramadass T, Manokaran G, Pushpala SM, et al. Oral submucous fibrosis-New dimensions in surgery[J]. Indian J Otolaryngol Head Neck Surg, 2005, 57(2): 99-102.
[31] Sudarshan R, Annigeri RG, Vijayabala GS. Aloe vera in the treatment for oral submucous fibrosis-a preliminary study[J]. J Oral Pathol Med, 2012, 41(10):755-761.
[32] Anil S, Beena VT. Oral submucous fibrosis in a 12-year-old girl: case report[J]. Pediatr Dent, 1993, 15(2):120-122.
[33] Katharia SK, Singh SP, Kulshreshtha VK. The effects of placenta extract in management of oral submucous fibrosis[J]. Indian J Pharmacol, 1992, 24(3):181-183.
[1] Chang Xinnan,Liu Lei. Applications and research progress of biodegradable magnesium-based materials in craniomaxillofacial surgery [J]. Int J Stomatol, 2024, 51(1): 107-115.
[2] Zhang Xidan,Sun Jiyu,Fu Xinliang,Gan Xueqi.. Research progress on the development of mesoporous calcium silicate nanoparticles in endodontics and repairing maxillofacial bone defects [J]. Int J Stomatol, 2022, 49(4): 476-482.
[3] Liang Yi,Pei Xibo,Wan Qianbing. Research progress on the biomedical applications of photosensitive hydrogels [J]. Int J Stomatol, 2022, 49(1): 12-18.
[4] Guo Yuting,Lü Xuechao. Research progress on drugs regulating the osteogenic differentiation of dental pulp stem cells [J]. Int J Stomatol, 2021, 48(6): 737-744.
[5] Li Yan,Meng Chenda,Xu Quanchen. Etiology and progress in the therapy of drug-induced gingival enlargement [J]. Int J Stomatol, 2020, 47(6): 693-698.
[6] Zhang Min,Wan Haoyuan. Research progress on drug and laser therapy for peri-implantitis [J]. Int J Stomatol, 2020, 47(4): 463-470.
[7] Wu Qiuyue,Li Zhibang. Research progress on the adjunctive drug therapy of peri-implantitis [J]. Int J Stomatol, 2020, 47(4): 471-477.
[8] Zhou Tingru,Li Yongsheng. Advances of dental pulp stem cells in osteogenic microenvironment [J]. Int J Stomatol, 2019, 46(6): 675-679.
[9] Jiang Xiaoge,Wu Jiaxin,Pei Xibo. Research progress on metal-organic frameworks and their complex in biomedical field [J]. Int J Stomatol, 2019, 46(5): 552-557.
[10] Cheng Guoping,Ding Yi,Guo Shujuan. Progress in electrospun fibres as periodontal drug delivery systems [J]. Int J Stomatol, 2019, 46(5): 565-570.
[11] Yuhao Liu,Quan Yuan,Shiwen Zhang. Recent research progress on the drug-loaded antibacterial coatings of titanium implants based on covalent grafting [J]. Inter J Stomatol, 2019, 46(2): 228-233.
[12] Changchang Ye, Lei Zhao, Dongqing Wang, Xiaoli Wang, Haiyan Wang, Meng You, Ping Huang, Yafei Wu. The treatment strategy of periodontal disease during pregnancy [J]. Inter J Stomatol, 2018, 45(5): 501-508.
[13] Jin Xin, Yang Junxing, Wang Yingnan, Liu Zhihui, Wang Bowei. Preparation and biomedical applications of alginate-chitosan microspheres [J]. Inter J Stomatol, 2018, 45(4): 414-419.
[14] Ji Ning, Zhao Hang, Zeng Xin, Chen Qianming. Research progress on nucleoside drugs against herpes virus [J]. Inter J Stomatol, 2018, 45(3): 351-357.
[15] Zhang Yixin, Li Lei. Development of calcium phosphate scaffolds as drug delivery system in bone tissue engineering [J]. Inter J Stomatol, 2018, 45(3): 346-350.
Full text



[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .